SIRT2 and breast carcinoma: Despite its therapeutic efficacy in breast cancer models [186], the poor aqueous solubility and laborious synthesis of the TM pseudopeptide Sirt2 inhibitor inspired conversion to thiocarbamoyl pseudopeptide analogs with improved solubility and decreased hydrophobicity [190].